Kurome Therapeutics is developing therapies that target cancer cells that have co-opted immune signaling pathways in order to avoid destruction by traditional therapeutic agents and subvert adaptive resistance mechanisms
Kurome Therapeutics is developing therapies that target cancer cells that have co-opted immune signaling pathways in order to avoid destruction by traditional therapeutic agents and subvert adaptive resistance mechanisms. The company is focused on developing a series of IRAK1/4, panFLT3 inhibitors for treating refractory/relapsed acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).